Co-Authors
This is a "connection" page, showing publications co-authored by JAMES P ALLISON and SANGEETA GOSWAMI.
Connection Strength
1.124
-
Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
Score: 0.222
-
The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 04; 11(4):838-857.
Score: 0.193
-
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020 06 17; 12(548).
Score: 0.183
-
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
Score: 0.177
-
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
Score: 0.160
-
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
Score: 0.052
-
Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021 04; 1489(1):30-47.
Score: 0.047
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.047
-
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
Score: 0.043